Driwan Stem Cell Therapy Information Center (continiu)

 

 

FOUNDER
 
Dr Iwan Suwandy,MHA
more infocontact
iwansuwandygmail.com
all free of charge
this info to all human in the world
with
 
THE MIGHTY GOD BLESS
 

International Hospital Yogyakarta

 Indonesia establish cooperation >>>

President Adi Husada hospital Indonesia, Guo Shao Lin and his wife received an invitation to visit the Cave
Joy Tobing do Anti-Aging in Modern Hospital Guangzhou (Stem Cell Research and Treatment Center >>>

Rumah Sakit Internasional Yogyakarta Indonesia membangun kerjasama >>>

 

Presiden rumah sakit Adi Husada Indonesia, Guo Shao Lin dan istri mendapat undangan berkunjung ke Gua

Joy Tobing melakukan Anti-Aging di Modern Hospital Guangzhou (Stem Cell Research and Treatment Center >>>

 

  • Sistm promosi pusat terapi stem cell guangzhao ini sangat cangih, tetapi tidak pernah menyeduakan info tentang berapa biaya terapi ini dan evaluasi hasil terapi secara patologis dan scanning serta pemeriksaan laboratorium lainnya sebelum dan sesudah terapi juga tidak tersedia seperti bagainan a perbaikan fungsi ginjal dengan  hasil pemeriksaan CCT pada urin 24 jam khususnya ekresi protei urine dan creatine serum sebagai alat penilai adanya kebocoran dari glomeruli ginjal.Namun stem terapi ini sangat menjanjikan dan perlu para ahli Indonesia dikirim ke pusat stem cell ini untuk belajar dan kemudian mengembangkannya di Indonesia.catatan Dr Iwan

 

 

 

 

 

Two professional chief physicians instruct the Internal Medicine Department (IMD). They use stem cell technology to treat many kinds of the complicated diseases that the IMD specialize in such as diabetes (type1,type2), apituitarism disease, hypothyroidism disease, idiopathic sarcoidosis, osteoporosis (embrace Perthes’ disease), rheumatoid arthritis , ankylosing spondylitis , systemic lupus erythematosus, vasculitis , sicca syndrome and so on.

 

They have treated about 300 patients successfully. The treatment is safe and reliable, the results are remarkable. The outcomes have significantly improved the patients’ quality of life.

 

Diabetes is a metabolic disorder which is the cause of many kinds of other diseases. Its main characteristic is chronic hyperglycemia. There are two reasons that cause the blood sugar levels to heighten. One is insulin secretion and the other is function flaw, another reason is that both conditions may exist. Diabetes is divides into type 1, type 2, and other special types, including gestational diabetes and so on.

 

With people’s living conditions improving, and as a result, life expectancy increasing worldwide, according to a WHO report, in 1997, there were about 135 millions diabetics in the world and this number is expected to rise to 300 millions by 2025.

 

Stem cell therapy is a new method; it was developed with molecular biology, molecular immunology and cell biology. It can treat diabetes from the cell and the gene level and cure diabetes on the clinical. It has minor side effects. The merits are the minor side effects and the steadying of the blood sugar levels. The effect is good.

 

 

 

We use self activation of the island Langerhans’ stem cell and stem cell transplantation to cure diabetes.

 

The types of transplantation cells are embryo stem cells, the insulin type of cell which originates in the embryo and develops into bone mesenchymal stem cells.

 

 

adma Shri Dr. V. Mohan is an eminent Indian Diabetologist who has been working in the field of diabetes for over 30 years in Chennai in southern India. Dr. Mohan is the Chairman and Chief of Diabetology at Dr. Mohan’s Diabetes Specialities Centre, a WHO Collaborating Centre for Noncommunicable Diseases Prevention and Control and an IDF Centre of Education.

 He is also President and Director of

 the Madras Diabetes Research Foundation.

Dr. Mohan completed his undergraduate (MBBS) and postgraduate medical education (MD, General Medicine) from Madras Medical College, Chennai, India. He then worked for a year as a Wellcome Trust Research Fellow at the Royal Postgraduate Medical School and Hammersmith Hospital, London, U.K and later for a year as an Alexander Von Humboldt Fellow at the University of Ulm, West Germany

 He was awarded a Ph.D.

and later a Doctor of Science (D.Sc.)

for his research on diabetes.

Prof. Mohan’s activities cover a wide range of clinical services, training and education, rural diabetes services and charity, research and public education and other activities on diabetes which are outlined below.

Dr. Mohan started working on diabetes as an undergraduate medical student when he joined his father late Prof. M. Viswanathan a pioneer in diabetes in India.

Together with his father, Dr. Mohan set up the first private diabetes centre in India in 1971 and continued to work at this centre till 1991. Dr. Mohan and his late wife Dr. Rema Mohan subsequently established their own diabetes centres under the name of

“Dr. Mohan’s Diabetes Specialities Centre”. 

Dr. Mohan and his colleagues currently oversee 13 diabetes centres and clinics in southern India and over 300,000 diabetic patients have been registered at these centres.

In 1996, Dr. Mohan established the Madras Diabetes Research Foundation (MDRF) in Asia. His research combines clinical, epidemiological and genomic aspects of diabetes. He has published nearly 834 papers including over 516 original research articles in peer reviewed journals, over 120 chapters in text books on diabetes, endocrinology and Internal Medicine and several invited reviews and editorials.

Dr. Mohan has received numerous awards and Fellowships. These includes the Padma Shri National Award by the Govt. of India for his accomplishments in the field of diabetology, Dr. BC Roy Award from the Medical Council of India and the Basanti Devi Amir Chand Prize from the Indian Council of Medical Research. Dr. Mohan was also awarded the Fellowships of the Wellcome Trust, UK and the Alexander Von Humboldt Foundation, Germany. He also received the Wockhardt Award for Medical Excellence from the Harvard Medical International, Boston. Dr. Mohan has been conferred Fellowships by all the four Royal Colleges of Physicians of London, Edinburgh, Glasgow and Ireland. He has also been elected Fellow of the National Academy of Sciences (FNASc).

Dr. Mohan’s work has been recognized by the World Health Organization (WHO) which has nominated his centre as a “WHO Collaborating Centre for Prevention and Control of Non-Communicable Diseases” as well as by the International Diabetes Federation (IDF) which nominated his centre as an “IDF Centre of Education”. He also serves on the Steering Committee of the Govt. of India’s National Program for Prevention and Control of Diabetes, Cardiovascular Diseases and Stroke (NPDCS) and on several other national scientific organizations. He is also a WHO Consultant on Diabetes and serves on several committees of the International Diabetes Federation.

 

Dr. V. Mohan receiving the Prestigious Padma Shri Award

 

 

 

 

 

 

 

 

 

 

 

Chennai: The Haven of Medical Research

Chennai has become the hotbed for breakthrough medical research work, thus attracting international collaborations, informs Nayantara Som.

Academicians in Hyderabad and Bangalore have competition now. There is another promising contestant in the race. Hitherto, Chennai was mainly associated with medical tourism, mushrooming hospitals and regular influx of patients. This is all passé. Now, the city seems to have gone through a metamorphosis. Today, walk into any hospital and, it is a common feature to see a separate research institute or a medical college attached, where intensive research work is deliberated upon and published.

“In diabetes, out of all Indian publications, around 40-50 per cent comes from Chennai”

 

– Dr V Mohan
Chairman
Dr Mohan’s Diabetes
Specialities Centre

Stem cell research, tissue engineering, molecular biology, nanotechnology, clinical and epidemiological studies, gene therapy, research in diabetes, you name it and Chennai has it all.

In diabetes alone, experts assert there is no competitor. Dr V Mohan, Chairman, Dr Mohan’s Diabetes Specialities Centre and President and Director of Madras Diabetes Research Foundation, Chennai, says,

“Chennai is definitely on the world map of medical research. In diabetes alone, if you browse through all the Indian publications, around 40-50 per cent comes from Chennai alone!”

 Prestigious institutes in the city like the Tuberculosis Research Centre, the Cancer Institute and the Madras Diabetes Research Foundation have come up with pioneering studies, making Chennai the locus of all research studies. Dr Sanjay Cherian, Managing Director, Frontier Lifeline, Chennai, says, “Chennai has a huge pool of experts and at the same time there is a large number of medical colleges growing rapidly.”

Collaborations with prestigious institutes abroad and in the country is a continuous process. Dr Samuel Abraham, Director, Nichi Centre for Regenerative Medicine (NCRM), Chennai, elaborates, “In Chennai, there are 14 or more institutes working on basic research and clinical applications of stem cell, which is the largest in any metro in the country, not only in number but also in diverse areas of the speciality.”

Research at some of the Hospitals

Frontier Lifeline

Its special unit, TICEL Bio Park is undertaking advanced research in Tissue Engineering

Sankara Nethralaya

Sankara Nethralaya is conducting research in nanotechnology for ophthalmology

MDRF, Chennai

The Madras Diabetes Research Foundation is specialising in genomics, clinical trials and vascular biology

NCRM, Chennai

NCRM is involved in the Chondrocytes for articular cartilage defect, Retinitis Pigmentosa, Cytotoxic T-Lymphocytes for Cancer and HIV, along with Biotherapy Institute, Japan

emodin inhibits 11β-HSD1 activity in 3T3-L1 adipocytes and improves inactive glucocorticoid-induced adipocyte dysfunction.

Diabetes

Stem Cell Research

Stem cell research is another prime area of focus for Chennai. “Research on cardiovascular diseases is ongoing by our genetic engineering lab,” says Dr Guhathakuta.

 In basic research, a project on bone marrow transplant is underway and is partly funded by the ICMR.

The Phase I trial with bone marrow derived stem cells with conditioning media is currently underway at the research facility at TICEL Bio Park.

In Phase II, progenitor cells harvested from blood and entirely autologous are the best cells available and ready for clinical use.

A technique is adopted whereby an injection (GcSF) is given for three days and subsequently the mononuclear stem cells are isolated by aphaeresis technique.

These cells are injected during surgery into the myocardium in the cardiac catheterisation laboratory.

 

This was performed in collaboration with Sri Venkateswara Institute of Medical Sciences, Tirupati. “This procedure has been performed in eight patients and another 20 patients are waiting,” says Dr S Cherian.

“The stem cells are separated and grown in Israel and used in Bangkok. There are more than 100 people waiting for this treatment. The cost in Bangkok for each patient is around $34,000 (including hospital stay).

In India, we could do it for $5,000,”says Dr KM Cherian.

Another project to look forward to is the Bio-Sciences Park, within the proposed Medicity, spearheaded by Frontier Lifeline, which will harbour a unit specially for R&D. Plans are on the anvil in which expert training, in the field of tissue engineering, for the whole of South East Asia will commence.

Again Sankara Nethralaya is involved in stem cell research like corneal limbal cell research.

If limbal stem cells are affected due to conditions such as acid or alkali burns, Steven Johnson syndrome etc, corneal grafting usually fails.

By transplanting limbal cells the success of grafting can be significantly improved.

 The practice has been to grow limbal stem cells on amniotic membranes.

Dr H N Madhavan, Director of research at Sankara Nethralaya was able to grow these limbal cells on a polymer (mebiol gel) in association with Dr Abraham from Japan.

We have been involved in this study since 2002 and after the animal experimentation which was completed, we are awaiting ICMR approval for the human trials.

 

The NCRM, Chennai (a Japanese collaboration) is collaborating with Sankara Netharalaya for this project.

The unique advantage here is there no usage of animal tissue or human tissue and so no possibility of rejection.

Cells are to be taken from patients’ own normal eye or normal portion of the affected eye.

One scientist is undergoing training for a year from an expert specialising in neuro stem cells.

There is research ongoing in neuro stem cells. Attempts are being made to convert a particular stem cell into a retinal nerve cell. “That, of course, is going to take decades before it can be introduced,” adds Dr Gopal.

Sankara Netharalaya has put in place multiple partnerships for research. Broad based MoUs have been inked with LV Prasad Eye Institute in Hyderabad and Aravind Eye Clinic, Madurai. “We are at a stage where we can bring together all our resources for better work,” says Dr Gopal. Other than broad-based agreements, there are individual-based agreements. The institute conducts drug trials for companies, with scientists from the US, New Zealand and Japan.

In technology,a recent acquisition is the Affymetrix machine, a state-of-art technology that does genetic analysis. Millions of genes can be looked and tested in one shot. An analysis that would take one year to identify the gene, will now take few days.

NCRM is also working on Corneal Endothelial Precursor Cells in collaboration with Tokyo University School of Medicine, who gave the technology and specimens and the harvesting was accomplished by Joseph Eye Hospital, Trichy.

This project is at the lab level and aims at treating bullous keratopathy, a disease that affects a lakh patients, each year. It affects the inner layer of the cornea, for which total corneal transplant is an option now. “By our technology, we have to take a few hundred cells from cadaver corneal endothelium (inner layer) and expand it to be put in the respective portion for cure, by doing which, the inner layer of cells of cornea of one cadaver eye can help recover the vision of a minimum of 40-60 people.”

Hurdles Faced

“Bangalore and Hyderabad boast of some of the best institutes in the country and the government allocates large amounts of money for infrastructure and development of these institutes. Chennai does not have such institutes and hence the opportunity for multisectoral research are less than Bangalore or Hyderabad,” says Dr Mohan who is also the President of the Madras Science Foundation. He, however, feels that there is enough funds available from various government agencies like ICMR, DBT, DST and CSIR.

“We need more money for medical research in India. It is currently difficult to get funds for medical research in our country. Similar to the situation in US and UK more organisations should donate money for medical research,” says Dr Viswanathan.

The Road Ahead

There are other experts in the city who beg to differ and are firm on their stand that Chennai rules the roost. Says Dr Abraham, “Though several prominent central government research institutes are present in Hyderabad and Bangalore (CCMB, IISc, NIMHANS), the gap between clinical faculty and basic sciences is too large in India. When an initiative is taken from clinical side the results are faster and better. This is where Chennai wins.”

The future is bright for Chennaites. “There is a lot in store for stem cell research. There is going to be stem cell research in plastic surgery, in orthopaedics and for cardio-vascular diseases,” says Dr S Cherian. In cases like diabetic ulcers and where a body part has to be amputated, stem cell therapy is a solution to free patients from this nightmare. Moreover in diabetes, large scale studies are on like the primary prevention programmes and awareness programmes. Experts also predict the coming together of biotechnological and pharmaceutical companies with the medical profession.

“A few partnerships are happening. The city is seeing and will see clinical trials, genetics, advances in insulin and vaccines and above all the why’s and how’s of diabetes,” says Dr Viswanathan.

 

 

 The Tuberculosis Research Centre is patenting a drug for HIV/AIDS. Construction of a new research facility of MDRF at SIRUSERI in the outskirts of Chennai is now nearing completion and is slated for inauguration in 2-3 months. This project will take the research at MDRF to the next level of basic research involving proteomics, tissue culture, stem cells and development of gene chips for accurate genomic classification of different subtypes of diabetes. As far as funding is concerned, institutes are concerned about solutions rather than whining about paucity. Collaborations both within and outside the country is a huge source for bringing in money. We sometime donate our own personal funds for conducting research projects.” says Dr. Viswanathan. “Sometimes hospital donate their own profits for the research projects,” adds Dr Viswanathan.

An optimistic approach is shared by a majority of experts from the city and perhaps it will be this approach which can keep Chennai ahead in the rat race.

nayantara.som@expressindia.com

 

Prof. John E. Rasko: Stem cell therapies at a crossroad

“Worldwide stem cell gene therapies are at a crossroad,” said Prof. Dr. John E. Rasko after the Universiti Tunku Abdul Rahman (UTAR) Seminar on Recent Advances in Stem Cell Research held at UTAR Sungai Long Campus on 25 May 2013.

Prof. Rasko, clinical hematologist, pathologist and scientist, is an Australian pioneer in the application of adult stem cell and genetic therapy.

  He directs the Department of Cell and Molecular Therapies at Royal Prince Alfred Hospital and heads the Gene and Stem Cell Therapy Programme at the Centenary Institute, University of Sydney. 

 He is the recipient of many national and international awards in recognition of his commitment to excellence in medical research, including appointment as an Officer of the Order of Australia.

 

“Stem cell therapy is at a crossroad of promises of new treatments versus unproven therapies,” Prof. Rasko elaborated, adding that many of these promises have turned to be false hopes for the people affected.

 In his two lectures, he said repeatedly that progress in stem cell therapy had always been ‘three steps forwards and two steps back’.

The situation is the same in Malaysia, where he said research in stem cells has generally been progressing well. 

While stem cell treatments are usually costly, unproven protocols bring no benefits and may even cause harm.

“As in many other countries, strict regulations must be established by the government to assure that people seeking stem cell treatments are not being taken advantage of by commercial interests,” Prof. Rasko’s message to Malaysia.

Prof. Rasko presented on two topics ‘Gene and Cell Therapy’ and ‘Haemopoiesis and the Stem Cell Niche’ at the seminar. 

 Prof. Dr. Tunku Kamarul from Universiti Malaya presented on ‘Stem Cell Research in Orthopaedics’, Dr Chin Sze Piaw from Cyopeutics Sdn Bhd lectured on ‘Current Clinical Applications of MSC in Malaysia’, and UTAR Centre for Stem Cell Research Chairperson Prof. Dr. Choo Kong Bung talked about ‘MicroRNAs in Stem Cells’.  Prof. Dr. Cheong Soon Keng, dean of UTAR Faculty of Medicine and Health Science, provided the opening remarks at the seminar.
 
The seminar attracted over 100 participants.  The sponsors of the seminar were All Eight Sdn Bhd, Axon Scientific Sdn Bhd, Biomarketing Sdn Bhd, Bita Lifescience Sdn Bhd, Matrioux Sdn Bhd and Stemedics Sdn. Bhd.

In the concluding remarks, Prof. Choo also announced that another one-day ‘UTAR Symposium on iPSC and Stem Cell Research: the Malaysian Scene 2013’ will be held on 29 November, 2013. The symposium will provide a platform for postgraduate students and young scientists in Malaysia to present their new research findings in stem cell research.

 

Prof. Rasko at the interview

 

VIPs at the seminar (from left): Prof. Cheong, Prof. Rasko, Prof. Choo, Prof. Kamarul and Dr. Chin

 

 

 

 

 

 

 

 

 

 

 

UTAR Centre

 for Stem Cell Research Chairperson

Prof. Dr. Choo Kong Bung

 

 

Members of the Centre for Stem Sell Research
 

No.

Member

Institution/ Faculty

Designation

E-mail

Research Area/ Interest

1

 

Emeritus Prof.
Dr. Cheong Soon Keng

UTAR FMHS

Dean;

Professorial Chair (Datuk and Datin Tan Kim Leong Professor of Medicine)

cheongsk@utar.edu.my

Blood cancer; dentritic cell vaccines; stem cells

2

Emeritus Prof.
Dr. Boo Nem Yun @ Mooi Nam Ying

UTAR FMHS

Deputy Dean (Academic Development and Undergraduate Programmes)

boony@utar.edu.my

G6PD deficiency-derived induced pluripotent stem cell (iPSC)

3

Prof. Dr. Choo Kong Bung

UTAR FMHS

Chairperson

Centre for Stem Cell Research

chookb@utar.edu.my

microRNA in cancer and stem cells

4

Prof. Dr Shelly Soo @ Soo Shelly

UTAR FMHS

Head of Department (Department of Medicine)

shellysoo@utar.edu.my

Cancer, stem cells

5

 

Assoc. Prof.
Dr Alan Ong Han Kiat

UTAR FMHS

Head of Programme (Postgraduate Programmes);

 

onghk@utar.edu.my

Cancer stem cells

6

 

Assoc. Prof.
Dr Gan Seng Chiew

UTAR FMHS

Associate Professor

gansc@utar.edu.my

iPSC derived from hair follicle keratinocytes

7

 

Assist. Prof.
Dr Leong Pooi Pooi

UTAR FMHS

Assistant Professor

Treasurer, CSCR

leongpp@utar.edu.my

Immunology; iPSC

8

Prof Dr Jenny Parameshvara Deva @ Nee Ng Gek Pheng

UTAR FMHS

Clinical Professor

Secretary, CSCR

jennypd@utar.edu.my

Genotype-phenotype in keratoconus/families; Stem cell research in treatment of ocular surface disorders

9

Prof. Dr M Parameshvara Deva a/l Muttu Ramalingam

UTAR FMHS

Professor

parameshvara@utar.edu.my

Mental illnesses

10 Assc. Prof. Dr Than Than Htwe UTAR FMHS

Associate Professor (Clinical)

thanth@utar.edu.my

Cancer research

No.

Associate member

Institution/ Faculty

Designation

E-mail

Research Area/ Interest

1

Dr Lim Kian Lam

UTAR FMHS;

Cryocord Sdn. Bhd.

Postdoctoral Fellow

promelkl@gmail.com

Stem cells

2

Wong Chee Yin

Cytopeutics Sdn. Bhd.

Chief Scientist

& PhD candidate

wongcyin@gmail.com

Mesenchymal stem cells in Regenerative medicine

3

Teoh Hoon Koon

PPUKM-MAKNA

Scientific Officer

& PhD candidate

hoonkoon@yahoo.com

Mesenchymal stem cells; RNAi;

iPSC; Disease Modelling

4

Erica Choong Pei Feng

PPUKM-MAKNA

Scientific Officer

erychoong@yahoo.com

Mesenchymal stem cells; Embryonic stem cells; iPSC

5

Liew Lee Chuen

PPUKM-MAKNA

Research Officer

& MSc. candidate

leechuen83@yahoo.com

Mesenchymal stem cells; Gene therapy

6

Ng Wei Yi

PPUKM-MAKNA

Research Officer

& MSc. candidate

ng_weiyi@hotmail.com

Immunobiology; Dendritic cell research

7

Nalini Devi A/P Verusingam

UTAR FMHS

MSc. candidate & Research assistant

nalinidv86@yahoo.com

Cancer stem cells; iPSC Regenerative medicine

8

Lim Sheng Jye

UTAR FMHS

MSc. candidate & Research assistant

shengjye2003@yahoo.com

Stem cells

9

Chiew Men Yee

UTAR FMHS

MSc. candidate & Research assistant

men-echiewf115@hotmail.com

Stem cells

10

   Soon Yuen Loon

UTAR FMHS

MSc. candidate & Research assistant

suen_yuenloon@hotmail.com

microRNA in cancer

11

Boo Lily

 

UTAR FMHS

Research assistant

ah_boo2001@yahoo.com

Cancer stem cells; iPSC

12

Norlaily Mohd Ali

 

UTAR FMHS

Research assistant

norlailyma@gmail.com

Mesenchymal stem cells

13

Teh Hui Xin

 

UTAR FMHS

Scientific Officer

tehhx@utar.edu.my

Stem cells

14

Ho Shu Cheow

UTAR FMHS

MSc. candidate & Research assistant

esther_sc87@hotmail.com

Stem cell; Hair regeneration

15

Nguyen Phan Nguyen Nhi

 

UTAR FMHS

Research assistant

nguyennhi204@hotmail.com

Stem cell ageing; microRNA

 

International Collaborators

 

Institution/Faculty

 

Designation

e-mail

Professor

Dr. Chiou Shih-Hwa

Department of Medical Research and Education, Taipei Veterans General Hospital &

Institute of Pharmacology, School of Medicine, National Yang-Ming University,  Taipei, Taiwan

 

Co-Director, Stem Cell Center, Taipei Veterans General Hospital

 

shchiou@vghtpe.gov.tw

Associate Professor

Dr. Huang Chiu-Jung

Department of Animal Science & Institute of Biotechnology,

College of Agriculture, Chinese Culture University, Taipei, Taiwan

 

Deputy Director, Office of Excellence in Teaching

hqr2@faculty.pccu.edu.tw

 

Stem cell terapi in Penang

 

 

 

Gleneagles Medical Centre Penang – overview

The Gleneagles Medical Centre is the pioneer private hospital in Penang. It is owned and managed by the Parkway Holdings Limited which operates other hospitals in neighboring countries. It is an acute care general hospital which specializes in a wide range of medical areas and equips advanced facilities.

 

It has been in service since 1973, and continues to provide quality care to both local and international patients until now.

 

 The Gleneagles Medical Centre Penang has undergone complete renovation from 1996 until 2000 which gave way for them to render the latest facilities for the best delivery of healthcare services. It is the first in the region to be awarded a three year full accreditation status by the Malaysian Society for Quality Health.

The Gleneagles Medical Centre has a total of 212 beds hospital-wide. There are over 40 professional doctors in the hospital designated in various specialty areas. The hospital offers foreign patient services which assists international patients and special packages for elderly people, pregnant women, and people seeking executive health screening programs.

Departments and specialty centers at Gleneagles Medical Centre Penang

        

        

        

       Bariatric Surgery

       Cardiac Surgery

       Cardiology

       Dialysis

       Endocrinology

       ENT

       Fertility Treatment

       Gastroenterology

       General Surgery

       Imaging

       Medical Check-ups

       Nephrology

       Neurology

       Neurosurgery

       Ob-Gyn

       Oncology

       Ophthalmology

       Orthopedics

       Pediatrics

       Rehabilitation

       Stem Cell Therapy

       Urology

Services

       Transportation services

       Family members can stay with patient

       Accommodation arrangements

Facilities

       Cafeteria/restaurant

       Recovery facilities

       Phone in rooms

       Internet connection

Certifications

       ISO 9001

Languages

       English

Numbers

       Number of doctors: 65

       Number of beds: 212

       Year established: 1973

 

 

 

 

Disclaimer:

The data provided in this page was collected from the Gleneagles Medical Centre Penang website (http://www.gleneagles-penang.com/), and other internet sources. last updated on Dec 26, 2013.
Please read our
disclaimer. If you have found any errors or missing data, please inform us.

Browse by specialty – Malaysia hospitals and clinics

       Aesthetics non surgical – Malaysia

 

 

Stem cell from fruit

Tripl3 Stemcell Miracle Intense Essence 100ml

Address: jalan new ferry
Location: Penang – Butterworth  
Postcode: 12100  
Price: RM 95    
Online Payment/Postage:
poslaju, airpak
     
     

 

 

Benefit of products, making skin more supple, narrow pores, make skin more detailed, reduce wrinkles, make the skin more youthful, Dilute the spot, make the skin more beautiful, enhance the skin and make the skin more elastics, antixidant skin care, keep youth look, SPF25UV protection from injury, Keep the skin fresh and moisturize, enhance the vitality of cells, making skin more firm, Whitening, making skin more evenly thorough, moisturizing the skin

Product Description

Just a spray may 10 miracle effectsSkin care has become a science in the modern, In addition to more women, many men also began to focus on the quality and safety of skin care products.

 

Our experts constantly to explore, finally got the breakthrough developed cell therapies Triple Stemcell Miracle Intense ESSENCE. In addition with PhytoCellTec Malus Domestica(Apple Stem Cell), PhytoCellTec Solar Vitis (Grape Stem Cell), PhytoCellTec Argan(Morocco Argan Fruit), DermCom Crocus Chrysanthus Bulb Extract(2012 Europh Innovation Prize),Hyaluronic Acid, Wheat Extract, Acid Hydrolyzed Cassava Extract, and has extensive with mineral springs.

Triple stemcell Miracle Intense Essence combining three kinds of plant stem cells, the invention won two European Innovation Invention Awards.

 

 

 

 

Twice Nobel Prize winner’s Dr. Linus Pualing recommended trace elements with small molecules and high penetrability , certainly be able to let you have immediate surface reaction, radiant, and confident.

 

 

Triple Stemcell Miracle Intense is very simple to use, after cleansing face, spray in the face. If there are some other parts, simply spray to see the miracle.

Uttwiller Spatlauber Apple Stemcell: Successfully developed by Mibelle Biochemistry chief scientist Dr Fred Zulli, this variety of apple stem cells can activate dormant stem cells in 80% of the human body cell regeneration and delay the aging process.

Gamay Teinturier Freaux Grape Stemcell: Successfully developed by Mibelle Biochemistry chief scientist Dr Fred Zulli, the product rich in anthocyanin pigments, delay the aging process effectively and prevent UV damage to skin tissue.

Argania Spinosa Morocco Argan Fruit: The world’s first proven have shown that the active substance having a dermal stem cells, the efficacy of protection and activation. Specifically for dermal stem cells ability to regenerate. In order to achieve a deep skin regeneration, skin restore firmness, and reduce wrinkles up to 26%.

DermCom Crocus Chrysanthus Bulb Extract: Won Innovation Award 2012 European invention, Its flower bulb extract based, by activating the communication between the cells of the skin, and thus reversed the degree of skin aging, the major applications are to promote the formation of collagen and elastin, improve skin density and help regain youth.

Sodium Hyaluronate: able to maintain skin elasticity, but also able to retain a relatively large amount of water , get smooth and moisturizing skin tissue, skin look plumpy, young and exlasting.

Wheat extract: By ECOCERT organic approval, Effectively inhibit the formation of melanin , but also to prevent UV-induced coloring, more rapid whitening.

Hydrolyzed cassava extract: Has immediate surface reaction, reduce wrinkles and fine lines, Firming the role of the skin

Mineral springs: Has a very rich trace elements, is a powerful anti-oxidant, fight again free radicals.

Copper: Neutralizes free radicals, contribute to the formation of collagen and elastin, and maintain the skin’s defense systems.
Selenium: against free radicals. Silicon: Contribute to the formation of collagen and elastin.
Zinc: can reduce the fine lines of the skin surface and uniform expression to the skin surface.
Magnesium: along with zinc to help skin tones.
Manganese: participate in the metabolism of collagen and eliminates free radical

Dr Linus Pualing YOU can trace every sickness, every disease and every aliment to a mineral deficiency

 

Nobel Prize winner’s Dr. Linus Pualing

Linus Pauling – Biographical

 

Linus Carl Pauling was born in Portland, Oregon, on 28th February, 1901, the son of a druggist, Herman Henry William Pauling, who, though born in Missouri, was of German descent, and his wife, Lucy Isabelle Darling, born in Oregon of English-Scottish ancestry.

Linus attended the public elementary and high schools in the town of Condon and the city of Portland, Oregon, and entered the Oregon State College in 1917, receiving the degree of B.Sc. in chemical engineering in 1922.

During the years 1919-1920 he served as a full-time teacher of quantitative analysis in the State College, after which he was appointed a Teaching Fellow in Chemistry in the California Institute of Technology and was a graduate student there from 1922 to 1925, working under Professor Roscoe G. Dickinson and Richard C. Tolman. In 1925 he was awarded the Ph.D. (summa cum laude) in chemistry, with minors in physics and mathematics.

 

Since 1919 his interest lay in the field of molecular structure and the nature of the chemical bond, inspired by papers by Irving Langmuir on the application of the Lewis theory of the sharing of pairs of electrons between atoms to many substances.

 In 1921 he suggested, and attempted to carry out, an experiment on the orientation of iron atoms by a magnetic field, through the electrolytic deposition of a layer of iron in a strong magnetic field and the determination of the orientation of the iron crystallises by polishing and etching the deposit, and microscopic examination of the etch figures.

With Professor Dickinson, he began in 1922 the experimental determination of the structures of some crystals, and also started theoretical work on the nature of the chemical bond.

Since his appointment to the Staff of California Institute of Technology, Professor Pauling was elected Research Associate in 1925; National Research Fellow in Chemistry, 1925-1926; Fellow of the John Simon Guggenheim Memorial Foundation, 1926-1927 (through this last he worked in European Universities with Sommerfeld, Schrödinger, and Bohr);

Assistant Professor of Chemistry, 1927-1929; Associate Professor, 1929-1931; Professor, 1931, when he was the first recipient of the American Chemical Society Award in Pure Chemistry – the Langmuir Prize – and Chairman of the Division of Chemistry and Chemical Engineering, and Director of the Gates and Crellin laboratories of Chemistry, 1936-1958.

 In 1963, he was awarded the Nobel Peace Prize.

Pauling is a member of numerous professional societies in the U.S.A. as well as in many European countries, India, Japan and Chile. Awards, medals, and honorary degrees were showered upon him in America and Europe, and in addition he was elected Rationalist of the Year for 1960 and Humanist of the Year for 1961.

 Several books have come from his pen, ranging from his most famous one The Nature of the Chemical Bond, and the Structure of Molecules and Crystals (1939, 1949, 1960) via General Chemistry (1947, 1953), which was translated into nine languages, to No More War! (1958, 1959,1962).

The subjects of the papers he published reflect his great scientific versatility: about 350 publications in the fields of experimental determination of the structure of crystals by the diffraction of X-rays and the interpretation of these structures in terms of the radii and other properties of atoms;

the application of quantum mechanics to physical and chemical problems, including dielectric constants, X-ray doublets, momentum distribution of electrons in atoms, rotational motion of molecules in crystals, Van der Waals forces, etc.;

 

 

the structure of metals and intermetallic compounds, the theory of ferromagnetism;

the nature of the chemical bond, including the resonance phenomenon in chemistry;

the experimental determination of the structure of gas molecules by the diffraction of electrons;

the structure of proteins;

the structure of antibodies and the nature of serological reactions;

 the structure and properties of hemoglobin and related substances;

abnormal hemoglobin molecules in relation to the hereditary hemolytic anemias;

 the molecular theory of general anesthesia;

an instrument for determining the partial pressure of oxygen in a gas; and other subjects.

Pauling married Ava Helen Miller of Beaver Creek, Oregon, in 1923. She is of English-Scottish and German descent. They have four children, Linus (Carl) Jr. (1925), Peter Jeffress (1931), Linda Helen (1932) and Edward Crellin (1937), and thirteen grandchildren.

From Nobel Lectures, Chemistry 1942-1962, Elsevier Publishing Company, Amsterdam, 1964

This autobiography/biography was written at the time of the award and first published in the book series Les Prix Nobel. It was later edited and republished in Nobel Lectures. To cite this document, always state the source as shown above.

 

Linus Pauling died on August 19, 1994

 

 

 

 

 

 

 

 

 

 

 

Stem cell terapi in Taipeh

Stem Cell Center

Taipei Veterams General Hospitals

 

Stem Cell Research Center – Taipei, Taiwan

Taipei Veterans General Hospital
No. 201, Sec. 2, Shih-Pai Road, Taipei 112
Taipei, Taiwan

Mission:

The Stem Cell Research Center of National Yang-Ming University focuses on studying stem cell biology, the characteristics and mechanisms of stem cells, and the applications of stem cells on human diseases. Applying stem cell therapy to repair injured cells and tissues, providing the adult stem cells in the body appropriate stimulation to regenerate vital organs, and exploring the role of stem cells in oncology and aging are the major interests of the center.

 

 

Director:

Oscar Kuang-Sheng Lee, MD, MSc, PhD

Background of Director:

The major research theme of Dr. Lee’s laboratory is plasticity and application of mesenchymal stem cells. Being an orthopaedic surgeon as well as a stem cell scientist, Dr. Lee is particularly interested in developing new application of mesenchymal stem cells to treat orthopaedic problems. The research interests also include osteoporosis, bone cell biology, and biophysical effects on bone cells and stem cells, and bone tumor biology. Dr. Lee is also the winner of Wu Ta-Yu Memorial Award from the National Science Council in Taiwan in 2006. In addition, he has been listed amongst the 2006-2007 International Who’s Who.

Major Accomplishments:

Dr. Lee’s lab has successfully isolated mesenchymal stem cells from human term umbilical cord blood. His work on this project was published in Blood on March 1, 2004 and his work was chosen as Cover Feature of that issue.

So far, this article has been cited more than 160 times. Also, his research team has demonstrated the differentiation potential of mesenchymal stem cells into hepatocytes in vitro and this has been published in Hepatology in December, 2004.

So far this article has been cited more than 110 times. The team also worked on an animal model of in utero transplantation of human mesenchymal stem cells into mice to investigate their in vivo differentiation potentials.

The team was able to demonstrate that human bone marrow-derived mesenchymal stem cells are able to differentiate into progenies originating from all three germ layers in vivo.

 

This work led to being awarded the New Investigator Recognition Award from the Orthopaedic Research Society in 2004.

 Importantly, the team also investigated the growth and differentiation of mesenchymal stem cells on Type 1 collagen nanofibers. This work has been published in Stem Cells in November 2006. Again his work was chosen as Cover Feature of that issue.

Current Projects:

The major research theme of Dr. Lee’s lab is plasticity and application of mesenchymal stem cells. Being an orthopaedic surgeon as well as a stem cell scientist, Dr Lee is particularly interested in developing new application of mesenchymal stem cells to treat orthopaedic problems.

The research interests also include osteoporosis, bone cell biology, and biophysical effects on bone cells and stem cells, and bone tumor biology.

The lab has successfully isolated mesenchymal stem cells from human term umbilical cord blood and this work has been published in Blood on March 1, 2004 and it has been chosen as Cover Feature of that issue.

So far, this article has been cited for more than 170 times. In addition, the research team has demonstrated the differentiation potential of mesenchymal stem cells into hepatocytes in vitro and this has been published in Hepatology in December, 2004 and the editorial highlight of the issue.

 So far this article has been cited for more than 110 times. The team also worked on an animal model of in utero transplantation of human mesenchymal stem cells into mice to investigate in their vivo differentiation potentials.

It has been demonstrated by us that that human bone marrow-derived mesenchymal stem cells are able to differentiate into progenies originated from all three germ layers in vivo.

This work leads to the winning of New Investigator Recognition Award from the Orthopaedic Research Society in 2004. Importantly, the team also investigated the growth and differentiation of mesenchymal stem cells on Type 1 collagen nanofibers. This work has been published in Stem Cells in November 2006 and again it was chosen as Cover Feature of that issue.

 


We have also looked into the possibility of incorporating gene therapy with stem cells to further enhance bone formation and found that concomitant overexpression of Cbfb and Cbfa-1 can efficiently enhance osteogenic differentiation of MSCs.

The results of which have been published in Stem Cells in 2007. Changes of mitochondrial biogenesis during osteogenic differentiation were also studied in human MSCs.

The results showed that coordinated regulation of mitochondrial biogenesis and antioxidant enzymes occurs synergistically during osteogenic differentiation of human MSCs and have been published in Stem Cells in June 2008.

To follow up on our previous study published in 2004, we investigated the therapeutic potential of MSCs for treatment of liver disease using a mouse model of fulminant hepatic failure and found that MSCs effectively rescued fulminant liver failure in a pre-clinical mouse model.

This work has been published in Gastroenterology in Jun 2008 and the editorial highlight of the issue.

Recently, Dr Lee and his graduate students reported the existence of stem cells in anterior and posterior cruciate ligaments of the human knee joint, as well as in human parathyroid glands. Both manuscripts have already been accepted by Cell Proliferation.


Dr. Lee is the winner of Wu Ta-Yu Memorial Award from the National Science Council in Taiwan in 2006. Besides, he has been listed amongst the 2006-2007 International Who’s who. He was also invited as the discussion leader of Gordon Conference in 2008
.

Website:

http://www.ym.edu.tw/scrc/

 

All information is © 2013 by the Cell Therapy Foundation

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s